Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | STAT1 | P42224 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041317 | 0.92 | XDH (0.60) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7045828 | 0.89 | MAPT (0.66) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL762092 | 0.83 | MAPT (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7536897 | 0.80 | ALDH2 (0.77) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| Ipriflavone SCHEMBL111472 | 0.80 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| Ipriflavone SCHEMBL29485035 | 0.80 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12238018 | 0.79 | STS (0.77) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2070406 | 0.79 | NPC1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8816175 | 0.78 | MAPT (0.70) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28805339 | 0.78 | ALDH1A1 (0.70) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608089-B2 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2003-08-19 | — | — | US | disclosed |
| EP-1212312-B1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA SPA (IT) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
| EP-1212312-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017985-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | BRCA1, NCEH1, EZH1 | ALDH1A1 2996/4885MAPT 3858/4885SMN1; SMN2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.